Pirchio, R. http://orcid.org/0000-0003-1272-9328
Auriemma, R. S. http://orcid.org/0000-0002-1494-3419
Vergura, A. http://orcid.org/0009-0004-4483-0652
Pivonello, R. http://orcid.org/0000-0002-9632-1348
Colao, A. http://orcid.org/0000-0001-6986-266X
Funding for this research was provided by:
Università degli Studi di Napoli Federico II
Article History
Received: 20 June 2023
Accepted: 28 December 2023
First Online: 26 March 2024
Declarations
:
: AC has been Principal Investigator of Research Studies for Novartis, Ipsen, Pfizer, Lilly, Merck and Novo Nordisk; consultant for Novartis, Ipsen, Pfizer, and received honoraria from Novartis, Ipsen and Pfizer beyond the confines of this work. RPiv has been Principal Investigator of Clinical and/or Translational Research Studies for Novartis, HRA Pharma, Ipsen, Shire, Corcept Therapeutics, Cortendo AB, Janssen Cilag, Camurus, Strongbridge, and Pfizer; Co-investigator of Research Studies for Pfizer; received research grants from Novartis, Pfizer, Ipsen, HRA Pharma, Shire, IBSA, Strongbridge Biopharma; has been an occasional consultant for Novartis, Ipsen, Pfizer, Shire, HRA Pharma, Cortendo AB, Ferring, Strongbridge Biopharma, Recordati, Corcept Therapeutics, Crinetics Pharmaceuticals, ARH Healthcare, Biohealth Italia, Italfarmaco; and has received fees and honoraria for presentations from Novartis, Shire, Pfizer and Recordati beyond the confines of this work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: This study involved human participants. The study was conducted in accordance with the Declaration of Helsinki and “Federico II” Ethics Committee approved the study protocol (193/16).
: The patients included in the current study provided written informed consent with respect to a confidentiality statement of data collection according to the Italian privacy policy.